Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3620647 | 0.98 | HTR6 (0.57) | HTR6CYP3A4CYP2D6RAB9APKM | |
| Trifluoroacetic Acid SCHEMBL3622318 | 0.91 | HTR6 (0.52) | HTR6CYP3A4CYP2D6RAB9AHTR1A | |
| SCHEMBL3623167 | 0.90 | HTR6 (0.69) | HTR6CYP3A4CYP2D6RAB9A | |
| Trifluoroacetic Acid SCHEMBL3625913 | 0.89 | HTR6 (0.52) | HTR6CYP3A4CYP2D6RAB9AHTR1A | |
| SCHEMBL3622721 | 0.88 | HTR6 (0.61) | HTR6CYP3A4CYP2D6RAB9AHTR1A | |
| Trifluoroacetic Acid SCHEMBL3627076 | 0.81 | HTR6 (0.55) | HTR6CYP3A4CYP2D6RAB9AHTR1A | |
| SCHEMBL3624442 | 0.81 | HTR6 (0.80) | HTR6CYP3A4CYP2D6HTR1AHTR7 | |
| SCHEMBL3624420 | 0.80 | HTR6 (0.53) | HTR6CYP3A4CYP2D6SMN1; SMN2 | |
| SCHEMBL3623213 | 0.79 | HTR6 (0.51) | HTR6CYP3A4CYP2D6HTR1AHTR7 | |
| SCHEMBL3621706 | 0.78 | HTR6 (0.80) | HTR6CYP3A4CYP2D6HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812017-B2 | 4-substituted indole and indoline compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-10-12 | — | — | US | claimed |
| US-20080032968-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-02-07 | — | — | US | claimed |
| EP-2046741-B1 | INDOLES AS 5-HT6 MODULATORS | PROXIMAGEN LTD (GB) | 2012-10-31 | — | — | EP | disclosed |
| US-7812017-B2 | 4-substituted indole and indoline compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-10-12 | — | — | US | disclosed |
| US-7812017-B2 | 4-substituted indole and indoline compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-10-12 | — | — | US | disclosed |
| US-7812017-B2 | 4-substituted indole and indoline compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-10-12 | — | — | US | disclosed |
| US-20080032968-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-02-07 | — | — | US | disclosed |
| US-20080032968-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-02-07 | — | — | US | disclosed |
| US-20080032968-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032968-A1 | New compounds | HTR6, HTR1B, HTR1A | HTR6 1/4885CYP3A4 405/4885CYP2D6 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.